Skip to content
Review

The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.

Oct 2026 · Current opinion in clinical nutrition and metabolic care · 0 citations · 42 references
Medicine

Abstract

Purpose

OF REVIEW Obesity is an increasingly important health problem in older adults (≥65 years) and is associated with osteoarthritis, impaired mobility, reduced quality of life, cardiovascular disease, and other age-related comorbidities. This narrative review summarizes the current evidence regarding the benefits and risks of glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in older adults. RECENT

Findings

GLP-1 RAs, initially developed for the treatment of type 2 diabetes mellitus (T2DM), have emerged as effective pharmacological options for weight reduction and cardiovascular risk reduction. Studies suggest that GLP-1 RAs have clinically meaningful weight loss in older adults, with efficacy comparable to that observed in younger populations. In addition, selected GLP-1 RAs have demonstrated cardiovascular benefits, including reductions in major adverse cardiovascular events (MACE), which may be particularly relevant in older individuals with a high burden of cardiovascular disease. Nevertheless, several concerns should be considered before treatment initiation, including gastrointestinal intolerance, sarcopenia-related muscle loss, ophthalmologic complications, and hypoglycaemia when combined with insulin or sulfonylureas. Furthermore, polypharmacy and age-related physiological changes may increase the likelihood of clinically relevant drug interactions. SUMMARY Current evidence indicates that GLP-1 RAs may represent a valuable therapeutic option for carefully selected older adults, particularly those with severe obesity and cardiometabolic comorbidities.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.